Nishan Fernando, MD
Hematology & Oncology · Cumming, GANPI 1154309938
Payments from drug & device makers
Across 136 payments — averaging $28.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$973
- AstraZeneca$398
- Exelixis Inc.$361
- Pfizer$297
- Daiichi Sankyo Inc.$273
- Novartis$192
- plus $1K from 29 others
What the payments were for
- Consulting fees$95024%
- Speaking & faculty fees$852%
- Food & beverage$2,49864%
- Education$39010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 2 | $973 |
| AstraZeneca(2 entities) | 17 | $398 |
| Exelixis Inc. | 10 | $361 |
| Pfizer | 18 | $297 |
| Daiichi Sankyo Inc. | 12 | $273 |
| Novartis | 9 | $192 |
| Array Biopharma Inc | 18 | $175 |
| Sanofi | 3 | $150 |
| Merck | 4 | $108 |
| AbbVie | 4 | $97 |
| Tersera Therapeutics LLC | 3 | $87 |
| Johnson & Johnson(2 entities) | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $73 |
| Astellas Pharma US Inc | 2 | $55 |
| Incyte Corporation | 2 | $50 |
| Puma Biotechnology, Inc. | 2 | $49 |
| Beigene USA, Inc. | 2 | $44 |
| Eisai Inc. | 2 | $42 |
| Gilead | 2 | $37 |
| Myriad Genetic Laboratories, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $32 |
| Boehringer Ingelheim | 1 | $32 |
| Beone Medicines USA, Inc. | 1 | $32 |
| Stemline Therapeutics Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Deciphera Pharmaceuticals Inc. | 1 | $26 |
| Sobi, Inc | 1 | $23 |
| Mirati Therapeutics, Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $18 |
| Tempus AI, Inc | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Pharmaand GmbH | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Aliqopa$950
How this compares
$3,923 in reported general payments places this provider in the 40th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 25 | $414,406 |
| VenclextaVenetoclax | 16 | $347,677 |
| IbrancePalbociclib | 16 | $228,823 |
| XtandiEnzalutamide | 17 | $228,473 |
| Lenalidomide | 14 | $211,652 |
| BrukinsaZanubrutinib | 12 | $175,739 |
| TavalisseFostamatinib Disodium | 12 | $161,106 |
| EliquisApixaban | 89 | $58,102 |
| Imatinib Mesylate | 17 | $40,217 |
| XareltoRivaroxaban | 25 | $17,280 |
| Hydroxyurea | 72 | $1,829 |
| Abiraterone Acetate | 11 | $1,433 |
| ValacyclovirValacyclovir Hcl | 26 | $834 |
| Anastrozole | 40 | $570 |
| Ondansetron Hcl | 53 | $523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $18 | $414,40625 claims |
| AbbVieVenclexta | $97 | $347,67716 claims |
| PfizerIbrance, Eliquis | $297 | $286,925105 claims |
| Astellas Pharma US IncXtandi | $55 | $228,47317 claims |
| Beigene USA, Inc.Brukinsa | $44 | $175,73912 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $16 | $161,10612 claims |
| Johnson & JohnsonXarelto | $79 | $17,28025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Cumming
- Amelia ZelnakCumming$4.4M
- Ronald SteisCumming$705K
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Conor SteuerAtlanta$4.4M
- Anthony HunterAtlanta$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.